171 related articles for article (PubMed ID: 23570178)
1. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
[No Abstract] [Full Text] [Related]
2. SOP 01: Clinical investigations in CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():1-4. PubMed ID: 23570177
[No Abstract] [Full Text] [Related]
3. SOP 06: Selecting the participating centers and activation of a trial.
Onkologie; 2003 Oct; 26 Suppl 6():34-5. PubMed ID: 23570182
[No Abstract] [Full Text] [Related]
4. SOP 10: Study report and publication.
Onkologie; 2003 Oct; 26 Suppl 6():48-9. PubMed ID: 23570187
[No Abstract] [Full Text] [Related]
5. SOP 07a: Monitoring of a trial under CESAR responsibility.
Onkologie; 2003 Oct; 26 Suppl 6():38-40. PubMed ID: 23570184
[No Abstract] [Full Text] [Related]
6. SOP 13: Pharmacokinetic data analysis.
Onkologie; 2003 Oct; 26 Suppl 6():56-9. PubMed ID: 23570190
[No Abstract] [Full Text] [Related]
7. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
8. SOP 07: Data flow, monitoring, and archiving.
Onkologie; 2003 Oct; 26 Suppl 6():36-7. PubMed ID: 23570183
[No Abstract] [Full Text] [Related]
9. SOP 03: Preparation and structure of trial protocols.
Onkologie; 2003 Oct; 26 Suppl 6():11-4. PubMed ID: 23570179
[No Abstract] [Full Text] [Related]
10. SOP 04: Data collection forms (case report forms).
Onkologie; 2003 Oct; 26 Suppl 6():15-22. PubMed ID: 23570180
[No Abstract] [Full Text] [Related]
11. SOP 08: Reporting of adverse events.
Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
[No Abstract] [Full Text] [Related]
12. SOP 05: Patient information and informed consent.
Onkologie; 2003 Oct; 26 Suppl 6():23-33. PubMed ID: 23570181
[No Abstract] [Full Text] [Related]
13. SOP 12: Validation of bioanalytical methods.
Onkologie; 2003 Oct; 26 Suppl 6():52-5. PubMed ID: 23570189
[No Abstract] [Full Text] [Related]
14. SOP 14: Population pharmacokinetic analysis.
Onkologie; 2003 Oct; 26 Suppl 6():60-6. PubMed ID: 23570191
[No Abstract] [Full Text] [Related]
15. Trial watch: Lung cancer trial aims to bolster personalized medicine.
Harrison C
Nat Rev Drug Discov; 2014 Jun; 13(6):407. PubMed ID: 24875087
[No Abstract] [Full Text] [Related]
16. Next steps in clinical trial redesign.
Nicholas J
J Natl Cancer Inst; 2012 Jan; 104(2):90-2. PubMed ID: 22215851
[No Abstract] [Full Text] [Related]
17. European Commission considers revisions to clinical trials directive.
Mason E
J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
[No Abstract] [Full Text] [Related]
18. The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?
Piccart-Gebhart MJ
J Clin Oncol; 2014 Feb; 32(4):347-54. PubMed ID: 24366941
[No Abstract] [Full Text] [Related]
19. Scientific misconduct in investigational drug trials.
Shapiro MF; Charrow RP
N Engl J Med; 1985 Mar; 312(11):731-6. PubMed ID: 3974649
[No Abstract] [Full Text] [Related]
20. Ethical and Policy Issues for Seamless Phase I Oncology Trials.
Hutchinson N; Vinarov E; Iasonos A; Kimmelman J
J Clin Oncol; 2020 Mar; 38(7):669-673. PubMed ID: 31877086
[No Abstract] [Full Text] [Related]
[Next] [New Search]
